Fexofenadine/cyclodextrin inclusion complexation: Phase solubility, thermodynamic, physicochemical, and computational analysis

Drug Development and Industrial Pharmacy

Volumn 33, Issue 11, 2007, Pages 1205-1215

  Omari, Mahmoud M Al ^a   Badwan, Adnan A ^a   Zughul, Mohammad B ^b   Eric, J ^c   Davies, D ^c  

^a JORDANIAN PHARMACEUTICAL MANUFACTURING COMPANY   (Jordan)

^b UNIVERSITY OF JORDAN   (Jordan)

^c LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

1H NMR; Complex formation constants; Cyclodextrin inclusion complexation; Fexofenadine; Hydrophobic effect; Molecular modeling; Thermodynamics

Indexed keywords

CYCLODEXTRIN ALPHA; CYCLODEXTRIN BETA; CYCLODEXTRIN DERIVATIVE; CYCLODEXTRIN GAMMA; FEXOFENADINE; UNCLASSIFIED DRUG;

AQUEOUS SOLUTION; ARTICLE; COMPLEX FORMATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; ENTHALPY; HYDROPHOBICITY; IONIC STRENGTH; MATHEMATICAL COMPUTING; MOLECULAR MECHANICS; PH; PHYSICAL CHEMISTRY; PROTON NUCLEAR MAGNETIC RESONANCE; SOLID STATE; TEMPERATURE; THERMODYNAMICS; X RAY POWDER DIFFRACTION;

CALORIMETRY, DIFFERENTIAL SCANNING; CYCLODEXTRINS; HYDROGEN-ION CONCENTRATION; MAGNETIC RESONANCE SPECTROSCOPY; MODELS, MOLECULAR; OSMOLAR CONCENTRATION; SOLUBILITY; TERFENADINE; THERMODYNAMICS; X-RAY DIFFRACTION;

EID: 36749000569     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.1080/03639040701377672     Document Type: Article

References (36)

1. Al Omari, M. M., Zughul, M. B., Davies, J. E. D., & Badwan, A. A. (2006a). Sildenafil/cyclodextrin complexation: Stability constants, thermodynamics, and guest-host interaction probed by 1H-NMR and molecular modeling studies. J. Pharm. Biomed. Anal., 4, 857-865.
2. Al Omari, M. M., Zughul, M. B., Davies, J. E. D., & Badwan, A. A. (2006b). Effect of buffer species on the inclusion complexation of acidic drug celecoxib with cyclodextrin in solution. J. Incl. Phenom. Macrocyc. Chem., 55, 247-254.
3. Al Omari, M. M., Zughul, M. B., Davies, J. E. D., & Badwan, A. A. (2006c). Factors contributing to solubility synergism of some basic drugs with β-cyclodextrin in ternary molecular complexes. J. Incl. Phenom. Macrocyc. Chem., 54, 159-164.
4. Al Omari, M. M., Zughul, M. B., Davies, J. E. D., & Badwan, A. A. (2007) Effect of buffer species on the inclusion complexation of basic drug terfenadine with β-cyclodextrin in solution. J. Incl. Phenom. Macrocyc. Chem., 58, 227-235.
5. Backensfeld, T., Muller, B. W., & Kolter, K. (1991). Interaction of NSA with cyclodextrins and hydroxypropylcyclodextrin derivatives. Int. J. Pharm., 74, 85-93.
6. Badwan, A. A., Al Omari, M. M., Zughul, M. B., & Davies, J. E. D. (2005). Highly soluble binary cyclodextrin inclusion complexes. Patent No. EP1570862 A1. Application No. EP 2004-4227 20040225.
7. Chen, F, & Patel, M. V. (2000). Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents. Patent No. WO2000059475. Application No. WO2000-US7342 20000316.
8. Connors, K. A. (1997). The stability of cyclodextrin complexes in solution. Chem. Rev., 97, 1325-1358.
9. Dresser, G. K., Kim, R. B., & Bailey, D. G. (2005). Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: Possible role of organic anion transporting polypeptides. Clin. Pharmacol. Ther., 77, 170-177.
10. El-Barghouthi, M. I., Masoud, N. A., Al-Kafawein, J. K., Zughul, M. B., & Badwan, A. A. (2005). Host-guest interactions of risperidone with native and modified cyclodextrins: Phase solubility, thermodynamics and molecular modeling studies. J. Incl. Phenom. Macrocyc. Chem., 53, 15-22.
11. Esclusa-Diaz, M. T., Gayo-Otero, M., Perez-Marcos, M. B., Vila-Jato, J. L., & Torres-Labandeira, J. J. (1996). Preparation and evaluation of ketoconazole-β-cyclodextrin multicomponent complexes. Int. J. Pharm., 142, 183-187.
12. Fexofenadine hydrochloride USP monograph. (2006). In United States Pharmacopoeia (USP), 29th Edition, USP Convention (pp. 905-906). Maryland: INC.
13. Gladys, G., Claudia, G., & Marcela, L. (2003). The effect of pH and triethanolamine on sulfisoxazole complexation with hydroxypropyl-β- cyclodextrin. Eur. J. Pharm. Sci., 20, 285-293.
14. Henton, D. R., & Mccarty, F. J. (1995). Process for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs. Patent No. WO9531437. Application No. PCt/US95/04942.
15. Higuchi, T., & Connors, K. A. (1965). Phase solubility techniques. In C. N. Reilley (Ed.), Advances in analytical chemistry and instrumentation (Volume 4, pp. 117-212). New York: Wiley-Interscience.
16. Illum, L., Watts, P. J., & Cheng, Y. (2000). Novel formulations of fexofenadine. Patent No. WO2000021510. Application No. WO99-GB3396 19991012.
17. Kim, Y., Oksanen, D. A., Massefski, W., Blake, J. F., Duffy, E. M., & Chrunyk, B. (1998). Inclusion complexation of ziprasidone mesylate with β-cyclodextrin sulfobutyl ether. J. Pharm. Sci., 87, 1560-1567.
18. Kumar, N., Khanduri, C. H, & Sharma, M. (2000). Amorphos form of fexofenadine hydrochloride. Patent No. WO0071124. Application No. PCT/IB00/00708.
19. Li, P., Tabibi, S. E., & Yalkowsky, S. H. (1998). Combined effect of complexation and pH on solubilization. J. Pharm. Sci., 87, 1535-1539.
20. Lin, H., Yoo, J., Roh, H., Lee, M., Chung, S., Shim, C., & Kim, D. (2005). Transport of anti-allergic drugs across the passage cultured human nasal epithelial cell monolayer. Eur. J. Pharm. Sci., 26, 203-210.
21. Liu, L., & Guo, Q.-X. (2002). The driving forces in the inclusion complexation of cyclodextrins. J. Incl. Phenom. Macrocyc. Chem., 42, 1-14.
22. Menard, F. A., Dedhiya, M. G., & Rhodes, C. T. (1990). Physico-chemical aspects of the complexations of some drugs with cyclodextrins. Drug Dev. Ind. Pharm., 16, 91-113.
23. Meyer, G. A., Trespidi, L. A., Wilson, E. S., Clark, C. M., Desai, A. J., & Sancilio, F. D. (2002). Oral liquid compositions containing polymer- and carbohydrate-based dispersing agents. Patent No. US6365180. Application No. US99-354982 19990716.
24. Müller, B. W., & Albers, E. (1992). Complexation of dihydropyridine derivatives with cyclodextrins and 2-hydropropyl-β- cyclodextrin in solution. Int. J. Pharm., 79, 273-288.
25. Nalluri, B. N., Chowdary, K. P. R.,Murthy, K. V. R., Hayman, A. R., & Becket, G. (2003). Physicochemical characterization and dissolution properties of nimesulide-cyclodextrin binary systems. AAPS PharmSciTech. 4(1), Article 2 (http://www.pharmscitech.org).
26. Perlovich, G. L., Skar, M., & Bauer-Brandi, A. D. (2003). Driving forces and the influence of the buffer composition on the complexation reaction between ibuprofen and HPCD. Eur. J. Pharm. Sci., 20, 197-200.
27. Piel, G., Pirotte, B., Delneuville, I., Neven, P., Llabres, G., Delarge, J., & Delattre, L. (1997). Study of the Influence of both cyclodextrins and L-lysine on the aqueous solubility of nimesulide: Isolation and characterization of nimesulide-L-lysine-cyclodextrin complexes. J. Pharm. Sci., 86: 475-480.
28. Ribeiro, L., & Veiga, F. (2002). Complexation of vinpocetine with cyclodextrins in the presence or absence of polymers: Binary and ternary complexes preparation and characterization. J. Incl. Phenom. Macrocyc. Chem., 44, 251-256.
29. Russell, T., Stoltz, M., & Weir, S. (1998). Pharmacokinetics, pharmacodynamics, and tolerance of single- and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin. Pharmacol. Ther., 64, 612-621.
30. Tannergren, C., Petri, N., Knutson, L., Hedeland, M., & Lennernas, H. (2003). Multiple transport mechanisms involved in the intestinal absorption and first-pass extraction of fexofenadine. Clin. Pharmacol. Ther., 74, 423-436.
31. Taraszewska, J., Migut, K., & Kozbiat, M. (2003). Complexation of flutamide by native and modified cyclodextrins. J. Phys. Org. Chem., 16, 121-126.
32. Tinwalla, A. Y., Hoesterey, B. L., Xiang, T., Lim, K., & Anderson, B. D. (1993). Solubilization of thiazolobenzimidazole using a combination of pH adjustment and complexation. Pharm. Res., 10, 1136-1143.
33. Ventura, C. A., Giannone, I., Paolino, D., Pistara, V., Corsaro, A., & Puglisi, G. (2005). Preparation of celecoxib-dimethy-β-cyclodextrin inclusion complex: Characterization and in vitro permeation study. Eur. J. Med. Chem., 40, 624-631.
34. Williams, R. O., Johnston, K. P., Young, T. J., Rogers, T. L., Barron, M. K., Yu, Z., & Hu, J. (2002). Process for production of nanoparticles and microparticles by spray freezing into liquid. Patent No. WO2002060411. Application No. WO2002-US2894 20020130.
35. Yoshida, A, Yamamoto, M, Irie, T, Hirayama, F, & Uekama, K. (1989). Some pharmaceutical properties of 3-hydroxypropyl- and 2,3-dihydroxypropyl-beta- cyclodextrins and their solubilizing and stabilizing abilities. Chem. Pharm. Bull., 37, 1059-1063.
36. 2 type phase solubility diagrams, complex formation and chemical speciation of soluble species. J. Incl. Phenom. Macrocyc. Chem., 31, 243-264.